Definitive Contract HHSN272201600037C
Award Date
8/29/16
Potential Completion Date
8/30/18
Potential Value
$442K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
PAI Life Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The $2,338,680.13 definitive contract is for the Phase II development of a prophylactic onchocerciasis (river blindness) vaccine under the SBIR program. The contract is a cost plus fixed fee arrangement with a completion date of May 15, 2024. PAI Life Sciences is collaborating with Thomas...
This is a $444,428 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of a Leishmania vaccine, combining parasite and vector components. This contract was designated as a total small business set-aside. PAI Life Sciences has a history of securing federal contracts and grants, particularly from NIAID, for the development of vaccines and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded PAI Life Sciences Inc. a $597,953 definitive contract to develop late stage adjuvant mimics based on toll-like receptor 4 agonists. As a self-certified small disadvantaged business, this contract was designated as a total small business set aside. PAI Life Sciences will provide products and services to the National Institute of Allergy and Infectious Diseases in support of their program for late stage...
This is a $1,486,937 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of an inhaled drug combination for tuberculosis therapy under the SBIR Phase II program. Key tasks include the manufacture of spray-dried combination drugs, technical support for pharmacokinetic and...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This federal contract award, valued at $210,507.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business, for the "AEROSOLIZED DELIVERY OF ANTI-TUBERCULAR DRUGS" project. The contract is a Definitive Contract with a Firm Fixed Price pricing type. PAI Life Sciences will be the prime contractor, and Research Triangle Institute (RTI International), a non-profit research organization, will...
This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), a civilian federal agency. The contract, valued at $4,328,663.00, is for expertise in the product development lifecycle, including services such as cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management for infectious...
This is a $300,000 firm fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Neovaxsyn Inc., a minority-owned, self-certified small disadvantaged business. The contract is for the development of a next-generation immunoprevention platform against HIV-1, with a total small business set-aside. The contract award is tied to a larger Small Business Innovation Research (SBIR)...
This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases under Broad Agency...